Thursday, July 17, 2014
Increased glucuronidation by activated hedgehog
signaling turns out to be the root of drug resistance for at least two
compounds in acute myeloid leukemia.1 Inhibiting the pathway could
avoid the toxicity of general glucuronidase suppression and boost the efficacy
of standard acute myeloid leukemia therapies.
Borden's study is the latest example of how the hedgehog
pathway helps cancers evade therapeutics, but this is the first time the
pathway has turned up as a driver of drug metabolism.
L. SciBX 7(27);
doi:10.1038/scibx.2014.785 Published online July 17, 2014
1. Zahreddine, H.A. et
al. Nature; published online May 28, 2014; doi:10.1038/nature13283
Contact: Katherine L.B. Borden, University of Montreal, Montreal, Quebec,
Canada e-mail: firstname.lastname@example.org
2. Zhao, C. et al. Nature
458, 776-779 (2009)
(NASDAQ:CRIS), Lexington, Mass.
South San Francisco, Calif.
(NYSE:PFE), New York, N.Y.
Pharmascience Inc., Montreal, Quebec, Canada
(SIX:ROG;OTCQX:RHHBY), Basel, Switzerland
University of California, San Diego, La Jolla, Calif.
University of Montreal, Montreal, Quebec, Canada